Tenet Healthcare Corporation (NYSE:THC) has quietly become one of the strongest-performing healthcare stocks in the market, surging more than 270% over the past five years. That rally reflects a business that has changed significantly: Tenet (NYSE:THC) has expanded its ambulatory surgery platform, increased its focus on higher-acuity care, and materially improved cash generation.
The latest results suggest that transformation is still gaining momentum. The company delivered another earnings beat and raised its full-year outlook as stronger hospital profitability and continued growth at its outpatient surgery platform supported performance.
However, after such a rise in the share price, the question for investors is no longer whether Tenet’s (NYSE:THC) turnaround is working. It is whether the company can continue expanding margins and growing earnings as surgical volumes soften and payer-mix pressures increase.
Bull Case
The company recently reported strong fiscal Q2 2026 results, surpassing Wall Street estimates with adjusted diluted earnings per share increasing 52.2% to $6.12, compared to $4.02 in the prior year period. Net operating revenue rose 6.8% year over year to $5.63 billion, supported by growth across both the hospital and ambulatory segments. Both operating segments contributed to the quarter, with ambulatory revenue increasing 9.3% to approximately $1.39 billion and hospital revenue rising 6.0% to approximately $4.20 billion. More importantly, the hospital segment, and not only the faster-growing ambulatory business, delivered meaningful earnings improvement, making the quarter’s strength more broad-based.
The results suggest that Tenet’s (NYSE:THC) continued focus on higher-acuity hospital services and the expansion of its ambulatory platform are improving profitability. Overall, adjusted EBITDA rose to $1.30B from $1.12B, supported by strong same-facility revenue growth and disciplined expense management.
The strongest evidence supporting Tenet’s (NYSE:THC) investment case is the sharp improvement in hospital profitability. Hospital adjusted EBITDA margin expanded from 15.6% to 18%. This occurred despite an unfavorable payer mix caused by lower exchange admissions. Hospitals are operationally complex, labor-intensive businesses, so meaningful margin expansion is difficult to achieve. The combination of revenue growth and margin expansion indicates that Tenet (NYSE:THC) is generating operating leverage rather than merely becoming a larger business.
Same-hospital admissions increased 2.3%, while adjusted admissions rose 2.6%. Management described the sequential improvement in adjusted admissions as further evidence that the underlying demand environment remains healthy. This suggests that the volume weakness was concentrated in USPI’s same-facility surgical cases rather than across Tenet’s entire portfolio.
Tenet (NYSE:THC) raised its full-year 2026 outlook on the strong quarter, and now expects adjusted EBITDA of $4.83B-$5.03B, up from the previous range of $4.48B-$4.78B. The company also raised its net operating revenue guidance to $21.9B-$22.5B from $21.5B-$22.3B and adjusted free cash flow forecast to $2.73B-$3.03B from $2.50B-$2.80B. The guidance increase was not driven solely by favorable reimbursement items. Management also pointed to stronger underlying volumes, revenue growth, and operating performance. This is significant for investors because a guidance increase based largely on nonrecurring payments would be less valuable than one supported by core operations.
Bear Case
One of the biggest concerns for investors is that Tenet’s (NYSE:THC) surgery business is generating stronger financial results despite performing fewer procedures. Surgical business same-facility system-wide net patient service revenues rose 5.0%, but cases were down 1.2% while net revenue per case went up 6.3%, reflecting its high acuity focus. This raises the question of whether earnings growth can remain strong if procedure volumes continue to weaken. Higher revenue per case can offset weaker volumes in the near term, but it is unlikely to support the same growth rate indefinitely. If procedure volumes remain negative and revenue-per-case growth normalizes, USPI’s earnings growth could slow.
Another important risk is the deterioration in payer mix. Management noted that lower exchange enrollment was being accompanied by an approximately corresponding increase in uninsured patients. Tenet (NYSE:THC) absorbed the pressure during the quarter through stronger hospital revenue, higher acuity and disciplined expense management, but continued weakness in payer mix could weigh on revenue quality and profitability if the trend persists.
Tenet’s (NYSE:THC) recent hospital margin expansion also creates a demanding comparison for future periods. After the hospital adjusted EBITDA margin rose 240 basis points to 18.0%, investors should not assume that margins can continue expanding at the same pace. Future earnings growth may increasingly depend on admission growth, revenue per patient, and continued cost discipline rather than another similarly large margin increase.
While Tenet’s (NYSE:THC) current growth is being supported by both stronger hospital volumes and higher-value outpatient procedures, investors should keep in mind that USPI’s negative same-facility case growth means the quality and sustainability of that growth may still require scrutiny.
While we acknowledge the risk and potential of THC as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than THC and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.
Disclosure: None. Follow Insider Monkey on Google News.
